Koers MEDIGENE NA Swiss Exchange
Aandelen
OXMDGG
DE0005020903
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- EUR | - |
Omzet 2024 * | 10,6 mln. 11,55 mln. | Omzet 2025 * | 6,95 mln. 7,57 mln. | Marktkapitalisatie | 37,73 mln. 41,13 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -11,99 mln. | Nettowinst (verlies) 2025 * | -17 mln. -18,53 mln. | EV/omzet 2024 * | 5,16 x |
Nettoschuld 2024 * | 17 mln. 18,53 mln. | Nettoschuld 2025 * | 14 mln. 15,26 mln. | EV/omzet 2025 * | 7,44 x |
K/w-verhouding 2024 * |
-3,46
x | K/w-verhouding 2025 * |
-2,29
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,05% |
Recentste transcriptie over MEDIGENE NA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 25-07-22 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-14 |
Pamela Keck
IRC | Investor Relations Contact | - | 01-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 66 | 12-08-16 | |
Frank Mathias
BRD | Director/Board Member | 62 | 15-05-18 |
Anthony Man
BRD | Director/Board Member | 68 | 16-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,33% | 125 mld. | |
+13,95% | 108 mld. | |
-3,53% | 24,57 mld. | |
+4,40% | 22,82 mld. | |
-10,42% | 18,19 mld. | |
-41,48% | 16,54 mld. | |
-12,62% | 16,5 mld. | |
+0,99% | 13,39 mld. | |
+21,79% | 11,1 mld. |
- Beurs
- Aandelen
- Koers MDG1
- Koers OXMDGG